In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor by Heather Zhang, Ying C. Ou, Dan Su, Fan Wang, Lai Wang, Srikumar Sahasranaman, Zhiyu Tang

Connect to this object online.

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator by Kun Wang, Xueting Yao, Miao Zhang, Dongyang Liu, Yuying Gao, Srikumar Sahasranaman, Ying C. Ou

Connect to this object online.

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies by Ying C. Ou, Lucy Liu, Bilal Tariq, Kun Wang, Ashutosh Jindal, Zhiyu Tang, Yuying Gao, Srikumar Sahasranaman

Connect to this object online.

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors by Nageshwar Budha, Chi‐Yuan Wu, Zhiyu Tang, Tian Yu, Lucy Liu, Fengyan Xu, Yuying Gao, Ruiying Li, Qiuyang Zhang, Ya Wan, Srikumar Sahasranaman

Connect to this object online.

Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors by Tian Yu, Xiangyu Liu, Chi‐Yuan Wu, Zhiyu Tang, Hongwei Wang, Patrick Schnell, Ya Wan, Kun Wang, Lucy Liu, Yuying Gao, Srikumar Sahasranaman, Nageshwar Budha

Connect to this object online.